2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W010451
    1,2,4-Trihydroxybenzene 533-73-3 ≥98.0%
    1,2,4-Trihydroxybenzene (Hydroxyhydroquinone) is an ER stress inducer that targets proteins such as PKR-like ER kinase PERK to induce cytotoxicity. 1,2,4-Trihydroxybenzene selectively activates eIF2α phosphorylation, activates the PERK-eIF2α signaling pathway and induces stress granule formation. 1,2,4-Trihydroxybenzene subsequently exacerbates oxidative stress and causes DNA double-strand breaks, destroying organelles such as mitochondria and ER, and inducing cell death. 1,2,4-Trihydroxybenzene also has the potential to exhibit anti-tumor effect, increase blood pressure, and relieve spasm.
    1,2,4-Trihydroxybenzene
  • HY-W010918S2
    Adenosine 5'-diphosphate-15N5 dilithium
    Adenosine 5'-diphosphate-15N5 (Adenosine diphosphate-15N5 dilithium) dilithium is 15N labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P2T-purinoceptors.
    Adenosine 5'-diphosphate-15N5 dilithium
  • HY-W013175S2
    Uridine 5'-monophosphate-13C9,15N2 disodium 99.77%
    Uridine 5'-monophosphate-13C9,15N2 disodium is the 13C and 15N labeled Uridine 5'-monophosphate disodium salt (HY-W013175). Uridine 5'-monophosphate (5'-Uridylic acid) disodium salt is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate disodium salt can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea.
    Uridine 5'-monophosphate-13C9,15N2 disodium
  • HY-100771
    PCC0208009 1668565-74-9 98.06%
    PCC0208009 is a potent IDO inhibitor with an IC50 value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala .
    PCC0208009
  • HY-15472
    PRX-08066 866206-54-4
    PRX-08066 is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 inhibits pulmonary vascular remodeling. PRX-08066 can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET).
    PRX-08066
  • HY-112815
    ALK2-IN-2 2254409-25-9 99.93%
    ALK2-IN-2 is an orally active and selective inhibitor of ALK2 (ACVR1), with an IC50 value of 9 nM, and over 700-fold selectivity against ALK3. ALK2-IN-2 can inhibit oxidative stress and protect endothelial cells.
    ALK2-IN-2
  • HY-115486
    MPO-IN-28 37836-90-1 98.11%
    MPO-IN-28 is a selective myeloperoxidase (MPO) inhibitor with an IC50 of 44 nM. MPO-IN-28 can effectively inhibit MPO-mediated low-density lipoprotein oxidation with an IC50 of 90 nM.
    MPO-IN-28
  • HY-118284
    Vicagrel 1314081-53-2 99.92%
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Vicagrel
  • HY-153491
    Olezarsen 2097587-83-0
    Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease.
    Olezarsen
  • HY-P0119A
    Lixisenatide acetate 1997361-87-1 99.11%
    Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.
    Lixisenatide acetate
  • HY-15851
    Revefenacin 864750-70-9 99.09%
    Revefenacin (TD-4208; GSK1160724) is a potent mAChR antagonist; has a high affinity on M3 receptor with a Ki of 0.18 nM.
    Revefenacin
  • HY-109136
    Runcaciguat 1402936-61-1 99.31%
    Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF).
    Runcaciguat
  • HY-122908
    Atuliflapon 2041075-86-7 98.97%
    Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC50 of 2 nM. Atuliflapon is used in the study for coronary artery disease.
    Atuliflapon
  • HY-145607
    Zagociguat 2201048-82-8 99.09%
    Zagociguat (CY-6463) is an orally active and BBB-permeable soluble guanylate cyclase (sGC) stimulator. Zagociguat can increase cGMP levels, regulate blood pressure, improve neuronal function, reduce inflammatory responses, and exert neuroprotective and cognitive-improving effects. Zagociguat can be used in the research of neurodegenerative diseases.
    Zagociguat
  • HY-119350B
    Zalunfiban dihydrochloride 2815778-41-5 99.07%
    Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI).
    Zalunfiban dihydrochloride
  • HY-14739
    Choline Fenofibrate 856676-23-8 99.54%
    Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect.
    Choline Fenofibrate
  • HY-14950
    Dalcetrapib 211513-37-0 99.19%
    Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively.
    Dalcetrapib
  • HY-15799
    AZD1283 919351-41-0 99.33%
    AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders.
    AZD1283
  • HY-18763
    Indobufen 63610-08-2 99.98%
    Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.
    Indobufen
  • HY-19360
    Sulprostone 60325-46-4 ≥99.0%
    Sulprostone (SHB 286) is a potent and selective EP3 receptor agonist. Sulprostone (SHB 286) is a prostaglandin E2 (PGE2) analogue and has antiulcer and nonsteroidal abortifacient effects. Sulprostone has potential for the research of pregnancy termination and hemorrhages during delivery.
    Sulprostone
Cat. No. Product Name / Synonyms Application Reactivity